Here's why Merck would pay nearly $4M for Idenix, more than triple its value
June 09, 2014 at 14:55 PM EDT
Why would a drug giant like Merck & Co. be so interested in getting into the crowded field of hepatitis C treatments that it’s willing to acquire a Cambridge company for more than triple its valuation as of last week? The $3...
